The purpose of this study is to compare and explore bioavailability of mosapride, the main component of DWJ1252(Test drug) and mosapride medicine(Reference drug).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
30
tablet(oral) administration following the schedule of each arm
Seoul National University Hospital
Seoul, South Korea
Pharmacokinetics of Mosapride
AUC(0-last), Cmax
Time frame: 48hr after 1st administration
Pharmacokinetics of mosapride, M-1
* AUCoo, tmax, t 1/2, CL/F, Vd/F of Mosapride * AUC(0-last), AUCoo, Cmax, tmax, t 1/2 of M-1
Time frame: 48hr after 1st administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.